Is mild cognitive impairment a valid target of therapy

Canadian Journal of Neurological Sciences

Volumn 34, Issue SUPPL. 1, 2007, Pages

  Rockwood, Kenneth ^a,d   Chertkow, Howard ^b   Feldman, Howard H ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Centre for Health Care of the Elderly   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; AMNESIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; KORSAKOFF PSYCHOSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

EID: 34248591280     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100005643     Document Type: Conference Paper

References (74)

1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256:240-6.
2. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004; 61:59-66.
3. Ingles JL, Fisk JD, Merry HR, Rockwood K. Five-year outcomes for dementia defined solely by neuropsychological test performance. Neuroepidemiology. 2003;22:172-8.
4. MacKnight C, Graham J, Rockwood K. Factors associated with inconsistent diagnosis of dementia between physicians and neuropsychologists. J Am Geriatr Soc. 1999;47:1294-9.
5. Davis H, Rockwood K. Conceptualization of mild cognitive impairment: a review. Int J Geriatr Psychiatry. 2004;19: 313-9.
6. Panza F, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry. 2005;13:633-44.
7. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
8. Streiner D, Norman G. Health Measurement Scales: a guide to their development and use. 3rd ed. Oxford: Oxford University Press; 2003.
9. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW Jr, Rubin EH, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001;56:361-7.
10. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-92.
11. de Mendonca A, Ribeiro F, Guerreiro M, Garcia C. Frontotemporal mild cognitive impairment. J Alzheimers Dis. 2004;6:1-9.
12. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115-21.
13. Fisk J, Merry H, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179-84.
14. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC. Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med. 2003;33:1029-38.
15. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385-9.
16. Wahlund LO, Pihlstrand E, Jonhagen ME. Mild cognitive impairment: experience from a memory clinic. Acta Neurol Scand Suppl. 2003;179:21-4.
17. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793-6.
18. Tuokko H, Frerichs R, Graham J, Rockwood K, Kristjansson B, Fisk J, et al. Five-year follow-up of cognitive impairment with no dementia. Arch Neurol. 2003;60:577-82.
19. Dwolatzky T, Whitehead V, Doniger GM, Simon ES, Schweiger A, Jaffe D, et al. Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatr. 2003;3:4.
20. Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol. 2004;63:641-9.
21. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med. 2004;256:205-23.
22. Kabani NJ, Sled JG, Chertkow H. Magnetization transfer ratio in mild cognitive impairment and dementia of Alzheimer's type. Neuroimage. 2002;15:604-10.
23. Mandzia J, Black S, Grady C, McAndrews MP, Graham S. Encoding and retrieval in aging and memory loss, a fMRI study. Brain Cogn. 2002;49:225-8.
24. Smith GE, Bohac DL, Waring SC, Kokmen E, Tangalos EG, Ivnik RJ, et al. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology. 1998;50:355-62.
25. Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand. 2003;107:390-3.
26. Royall DR, Chiodo LK, Polk MJ. Misclassification is likely in the assessment of mild cognitive impairment. Neuroepidemiology. 2004;23:185-91.
27. Jack CR Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004 24;62:591-600.
28. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology. 2004 Jul 27;63: 220-7.
29. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr. 2004;16:129-40.
30. Petersen RC. Challenges of epidemiological studies of mild cognitive impairment. Alzheimer Dis Assoc Disord. 2004;18:1-2.
31. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705-10.
32. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729-34.
33. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651-7.
34. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352:2379-88.
35. Johnson and Johnson Pharmaceutical Research and Development. Synopsis. GAL-INT-11. http://www.clinicalstudyresults.org./documents/company~study 961.pdf.
36. Johnson and Johnson Pharmaceutical Research and Development. Synopsis. GAL-INT-11. Available from: http://www.clinicalstudyresults.org./documents/ company~study962.pdf.
37. Schneider L. Mild cognitive impairment. Am J Geriatr Psychiatry. 2005;13:629-32.
38. Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis. 2005;7:235-9
39. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087-95.
40. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Aging Study (MRC CFAS). Lancet. 2001;357:169-75.
41. Wang DS, Bennett DA, Mufson E, Cochran E, Dickson DW. Decreases in soluble alpha-synuclein in frontal cortex correlate with cognitive decline in the elderly. Neurosci Lett. 2004;359:104-8.
42. Mufson EJ, Ma SY, Dills J, Cochran EJ, Leurgans S, Wuu J, et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002;443:136-53.
43. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469-90.
44. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-55.
45. Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci. 2003; 23:986-93.
46. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol. 2004;56:520-31.
47. Fisk JD, Rockwood K. Outcomes of incident mild cognitive impairment in relation to case definition. J Neurol Neurosurg Psychiatry. 2005;76:1175-7.
48. Kumar R, Dear KB, Christensen H, Ilschner S, Jorm AF, Meslin C, et al. Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: The personality and total health through life 60+ study. Dement Geriatr Cogn Disord. 2005;19:67-74.
49. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis. 2003;5:39-48.
50. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 1999;411:693-704.
51. Panza F, D'Introno A, Colacicco AM, Capurso C, Parigi AD, Capurso SA, et al. Cognitive frailty: predementia syndrome and vascular risk factors. Neurobiol Aging. 2006;27:933-40.
52. Thai LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind study of Rofecoxib in patients with mild cognitive impairment. Neuropsycho-pharmacology. 2005;3:1-12.
53. Morris JC. Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol. 2006;63:15-6.
54. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-83.
55. Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62:1199-201.
56. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 2000;355:225-8.
57. Steffens DC, Otey E, Alexopoulos GS, Butters MA, Cuthbert B, Ganguli M, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry 2006;63:130.
58. Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2 year follow up study. Dement Geriatr Cogn Disord. 2005;19:113-9.
59. Whitehouse PJ, Juengst ET. Antiaging medicine and mild cognitive impairment: practice and policy issues for geriatrics. J Am Geriatr Soc. 2005;53:1417-22.
60. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-8. Erratum in: Arch Neurol. 1999;56:760.
61. Bennett HP, Corbett AJ, Gaden S, Grayson DA, Kril JJ, Broe GA. Subcortical vascular disease and functional decline: a 6-year predictor study. J Am Geriatr Soc. 2002;50:1969-77.
62. Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59:1042-6.
63. Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand. 2002;106:148-54.
64. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le CN, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59:1594-9.
65. Lambon RMA, Patterson K, Graham N, Dawson K, Hodges JR. Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain. 2003;126(Pt 11):2350-62.
66. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004;63: 1898-901.
67. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, et al. Italian longitudinal study on aging working group. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882-91.
68. De Jager C, Blackwell AD, Budge MM, Sahakian BJ. Predicting cognitive decline in healthy older adults. Am J Geriatr Psychiatry. 2005;13:735-40.
69. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert M, Goodkind M. et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol. 2005;62:975-80.
70. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19: 383-9.
71. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-9.
72. Purser JL, Fillenbaum GG, Pieper CF, Wallace RB. Mild cognitive impairment and 10-year trajectories of disability in the Iowa established populations for epidemiologic studies of the elderly cohort. J Am Geriatr Soc. 2005;53:1966-72.
73. Visser P J, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2005;76:1348-54.
74. Verghese J, Le Valley A, Hall CB, Katz MJ, Ambrose AF, Lipton RB. Epidemiology of gait disorders in community-residing older adults. J Am Geriatr Soc. 2006;54:255-61.